XHKG
1643
Market cap61mUSD
Oct 09, Last price
0.58HKD
1D
-13.43%
1Q
-38.95%
IPO
-45.79%
Name
Modern Chinese Medicine Group Co Ltd
Chart & performance
P/E
—
P/S
2.52
EPS
—
Div yield, %
—
Shrs. gr., 5y
1.93%
Rev. gr., 5y
-14.45%
Revenues
141m
-33.94%
Net income
-13m
L
CFO
5m
-91.77%
Dividend
May 25, 20220.0167 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
As an investment holding company, Modern Chinese Medicine Group Co., Ltd. manufactures and distributes traditional Chinese pharmaceutical products, primarily targeting the middle-aged and elderly populations across the People's Republic of China. Its extensive product line provides treatments for a wide array of health issues, including qi deficiency, blood stasis, cardiovascular and cerebrovascular conditions, digestive and gastrointestinal ailments, gynecological problems, as well as disorders affecting the respiratory and nervous systems. Established in 1986, the enterprise maintains its principal offices in Chengde, China, and operates as a subsidiary of Modern Biotechnology Group Holdings Co., Ltd.
Key people
Hongli Zhang
Chief Executive Officer, Executive Director · since 2019
Chief Financial Officer · since 2020
Xinlei Sun
Executive Chairman of the Board · since 2023
Yanru Jia
Executive Director, Joint Company Secretary · since 2025
Yuen Ting Tse
Joint Company Secretary · since 2025
Tsz Wing Leung
Non-Executive Independent Director · since 2020
Ling Liu
Non-Executive Independent Director · since 2020
Chi Kin Wong
Non-Executive Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||